Eli Lilly's Zepbound and Other Weight-Loss Drugs to Be Covered Under Medicare Part D Starting July 1 at $50/Month
Miles Bennett
Eli Lilly's obesity drugs Zepbound and Foundayo will enter Medicare Part D on July 1 at $50 a month, marking the first large-scale federal coverage of GLP-1 weight-loss drugs and opening the single largest U.S. payer channel for Lilly.
What exactly is covered, and who qualifies?
The two drugs are Zepbound (tirzepatide) and Foundayo (orforglipron), both Eli Lilly obesity treatments.
Enrollees must meet Medicare GLP-1 Bridge clinical criteria and other CMS eligibility requirements to access the $50/month price.
This means → not every Medicare beneficiary qualifies automatically. The clinical threshold will filter out a portion of potential users; actual uptake depends on how large the eligible pool turns out to be.
What is the "bridge program"?
Coverage runs through a temporary bridge program effective July 1, 2026 through December 31, 2027 — an 18-month window.
In plain terms = federal Medicare is opening a trial door, not adding the drugs to its formulary permanently. Whether coverage continues after the window closes is a separate decision.
This reflects CMS's stance on GLP-1 drugs: it acknowledges their efficacy and is willing to test, but has not made a long-term fiscal commitment.
How will claims be processed?
CMS will route prior authorization, claims adjudication, and pharmacy reimbursement through a central processing entity, bypassing the usual plan-by-plan approval path.
This means → approval standards and turnaround times are unified nationally. Pharmacies get higher process certainty, helping Lilly scale the channel faster.
What does this mean for Lilly and the market?
Medicare is the largest single U.S. healthcare payer, covering more than 65 million people. Obesity drugs entering this channel for the first time raises the volume ceiling significantly.
The critical question lands at year-end 2027: whether coverage extends beyond the bridge period will determine if this channel delivers a short-term pulse or sustained volume growth.
In plain terms = Lilly has secured an 18-month admission ticket. Whether it becomes a permanent seat depends on whether the clinical data and the fiscal math hold up during the trial window.
Content is for reference only, not financial advice.